(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 6.03% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.3%.
Bioventus's revenue in 2026 is $581,848,000.On average, 6 Wall Street analysts forecast BVS's revenue for 2026 to be $51,448,253,103, with the lowest BVS revenue forecast at $49,822,757,062, and the highest BVS revenue forecast at $53,622,869,120. On average, 6 Wall Street analysts forecast BVS's revenue for 2027 to be $54,891,815,589, with the lowest BVS revenue forecast at $52,972,838,887, and the highest BVS revenue forecast at $58,020,033,525.
In 2028, BVS is forecast to generate $58,323,605,212 in revenue, with the lowest revenue forecast at $56,331,468,574 and the highest revenue forecast at $60,965,772,081.